Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2013 Aug;123(8):3190-200. doi: 10.1172/JCI70212. Epub 2013 Aug 1.

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Author information

  • 1Vesalius Research Center, University of Leuven, Leuven, Belgium.

Abstract

Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.

PMID:
23908119
[PubMed - indexed for MEDLINE]
PMCID:
PMC3726176
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Write to the Help Desk